https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_766dfc15212c4f2229458d806aeb7e5c.html ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 8, 2023. Registration No. 333-272628 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 6770 (Primary Standard Industrial Classification Code Number) 98-172573 (I.R.S. Emplo ...

Summary of Pfizer Inc. Conference Call Company Overview - **Company**: Pfizer Inc. (NYSE:PFE) - **Event**: Citi's 18th Annual BioPharma Conference - **Date**: September 7, 2023 Key Points Industry and Company Developments - **Strong R&D Year**: 2023 is highlighted as a strong year for Pfizer's R&D with nine approvals so far and expectations for up to six more [3][4] - **Notable Approvals**: Key products include: - PCV20: Pneumococcal vaccine for pediatrics - ABRYSVO: RSV vaccine with two approved indications - LITFULO: Novel TYK inhibitor for Alopecia - Etrasimod: New oral agent for inflammatory bowel disease pending final regulatory step [3][4] Acquisition and Integration - **Seagen Acquisition**: The acquisition of Seagen is a pivotal transaction for Pfizer, aimed at enhancing its oncology capabilities and integrating talent from Seagen into Pfizer's oncology R&D group [6][9] - **Oncology Focus**: The restructuring of Pfizer's oncology division is intended to capture the biotech spirit of Seagen and leverage its expertise in oncology [8][9] Product Pipeline and Innovations - **Vaccine Developments**: Pfizer is looking forward to concluding flu vaccine studies and has several intriguing readouts expected, including for sickle cell disease and gene therapy for DMD [5][21] - **Bispecific and Trispecific Antibodies**: Pfizer is advancing its portfolio in autoimmune diseases with bispecific and trispecific antibodies, aiming to enhance efficacy and tolerability [10][11][14] - **GDF15 Antagonist**: There is a growing enthusiasm for GDF15 antagonists in treating obesity and cachexia, with ongoing studies showing promising results [29][31] Market Strategy and Competitive Landscape - **RSV Vaccine Market**: Pfizer's RSV vaccine is the only one approved for two patient populations, with a strong market opportunity estimated at $1 billion to $1.2 billion [50] - **Pneumococcal Vaccine Leadership**: Pfizer has a stronghold in the pneumococcal vaccine market with innovations like PCV20 and plans to go beyond 20-valent vaccines [44][45] Future Outlook - **Oral GLP Drugs**: Pfizer is focusing on developing oral GLP drugs, with danuglipron data expected later this year, aiming to address obesity and diabetes [21][22][24] - **mRNA Technology**: Pfizer is prioritizing mRNA resources for vaccine development, particularly in flu and other respiratory diseases, while remaining cautious about entering the oncology therapeutic vaccine space [36][39][40] Regulatory and Market Considerations - **Vaccine Acceptance**: The acceptance of vaccines versus monoclonal antibodies in specific populations, such as pregnant women, is a key consideration for Pfizer's market strategy [50][52] - **Pricing Strategy**: Pfizer anticipates that any ACIP-recommended vaccine will be available at no out-of-pocket cost for insured individuals in the U.S., impacting market penetration strategies [58][60] Additional Insights - **Cultural Shift**: Pfizer is adopting a "risk curious" culture, encouraging thoughtful risks in innovation and development processes [34][35] - **Collaboration and Partnerships**: Pfizer is exploring collaborations with biotech firms to enhance its R&D capabilities and address significant medical challenges [34][39] This summary encapsulates the critical insights and developments discussed during the conference call, reflecting Pfizer's strategic direction and market positioning in the biopharmaceutical industry.

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_2fb34013243297e6020af4b6b0daf107.html ...

Pfizer Inc. (NYSE:PFE) Q2 2023 Results Conference Call August 1, 2023 10:00 AM ET Company Participants Chris Stevo - SVP and Chief IR Officer Dr. Albert Bourla - Chairman and CEO Dave Denton - CFO Dr. Mikael Dolsten - Chief Scientific Officer and President, Pfizer R&D Angela Hwang - Chief Commercial Officer and President, Global Biopharmaceuticals Business Aamir Malik - Chief Business Innovation Officer Dr. Chris Boshoff - Chief Oncology R&D Officer Conference Call Participants Nicole Germino - Truist Secur ...

Pfizer Inc. (NYSE:PFE) Goldman Sachs 44th Annual Global Healthcare Conference Call June 13, 2023 11:00 AM ET Company Participants William Pao - Chief Development Officer and Executive Vice President Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Good morning, everybody. Let's start on time. I hate to penalize people who are on time, especially in the morning. So welcome to day two, the Goldman Sachs Healthcare Conference. Hope everyone had a very positive and productive first d ...

Pfizer Inc. (NYSE:PFE) Q1 2023 Results Conference Call May 2, 2023 10:00 AM ET Company Participants Chris Stevo - SVP and Chief IR Officer Dr. Albert Bourla - Chairman and Chief Executive Officer Dave Denton - Chief Financial Officer Dr. Mikael Dolsten - President, Worldwide Research, Development and Medical Angela Hwang - Chief Commercial Officer and President, Global Biopharmaceuticals Business Aamir Malik - Chief Business Innovation Officer Dr. William Pao - Chief Development Officer Doug Lankler - Gener ...

Pfizer Invests $43B to Battle Cancer March 13, 2023 ...

43rd Annual TD Cowen Health Care Conference March 7, 2023 ...

Pfizer Inc. (NYSE:PFE) Cowen 43rd Annual Health Care Conference March 7, 2023 10:30 AM ET Company Participants Chris Stevo - SVP and Chief IR Officer Angela Hwang - CCO and President, Global Biopharmaceuticals Business Rodrigo Puga - U.S. Commercial and Global Business Lead for Internal Medicine Annaliesa Anderson - SVP and Chief Scientific Officer, Vaccine Research and Development Conference Call Participants Steve Scala - TD Cowen Steve Scala [Call Starts Abruptly] come back again this year. Representing ...